Bedford, United States
Stoke Therapeutics (Nasdaq: STOK) is a cutting-edge biotechnology company focused on pioneering RNA medicine designed to restore protein expression. Leveraging its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) technology, the company is at the forefront of developing antisense oligonucleotides (ASOs) aimed at selectively restoring protein levels.
Their lead product candidate, zorevunersen, has shown promising potential for modifying disease progression in Dravet syndrome, and it's currently undergoing a Phase 3 clinical study. Stoke Therapeutics initially targets conditions impacting the central nervous system and the eye, specifically those due to haploinsufficiency.
Founded in 2017 and based in Bedford, Massachusetts, the company has demonstrated proof of concept in multiple organs, suggesting a wide applicability for its approach. With no recent disclosed funding rounds, investors may view this as a focused opportunity in the high-impact realm of genetic medicine.
